Glaxo, US partnering to develop new antibiotics

by Hzl-Laj

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

will become a , experts predict, because most drug companies have cut investment in antibiotics. Instead, they're developing more-lucrative medicines for chronic conditions or rare disorders.

Glaxo's partnership with BARDA, the Biomedical Advanced Research and Development Authority within the Health and Human Services Department, will bring the British drugmaker $40 million over the first 18 months. If their agreement is renewed over five years, that could reach a total of $200 million.

Normally, such public-private agreements cover testing of one experimental drug. Glaxo says this is the first HHS deal giving a private company flexibility to test multiple potential drugs.

Related Stories

Elan enters $1B royalty deal with Theravance

date May 13, 2013

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Pharma's niche focus spurs US aid for antibiotics

date Jan 25, 2012

(AP) -- The pharmaceutical industry won approval to market a record number of new drugs for rare diseases last year, as a combination of scientific innovation and business opportunity spurred new treatments for diseases ...

US panel backs inhaler drug for lung disease

date Apr 17, 2013

A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.

Recommended for you

US aims to cut antibiotic use

date Mar 27, 2015

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

Questions over value of new antibiotics to tackle resistance

date Mar 26, 2015

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.